Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

← catalyst calendar

NCT03626688

Sponsored by United Therapeutics (industry) · UTHR — their whole pipeline →.

Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
687actual
Sites
209
Countries
Argentina, Australia, Austria +30

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2019-01-24actualWhen the study began enrolling
Primary completion2025-12-31actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-12-31actualThe whole study's end, after follow-up
First posted2018-08-13actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-06-16actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • PAH
  • Pulmonary Hypertension
  • Pulmonary Arterial Hypertension
  • Hypertension
  • Connective Tissue Diseases
  • Familial Primary Pulmonary Hypertension
  • Vascular Diseases
  • Cardiovascular Diseases
  • Hypertension, Pulmonary
  • Lung Diseases
  • Respiratory Tract Disease

Interventions

  • Drug: Ralinepag — also filed as APD811
  • Drug: Placebo

Primary outcome

what the primary-completion date above is the date OF
Time from randomization to the first adjudicated protocol-defined clinical worsening event
measured The study duration was event-based. This parameter was assessed from randomization until the conclusion of the study, up to 3 years

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · UTHR's whole pipeline · Catalyst calendar · Every registered study · What changed